Klinisk og kommersiell akselerasjon i Pharma Holdings

Offentlig prosjektsammendrag

The ambition during the two year project period is to accelerate the clinical and commercial development of the LTX-109 antiviral nasal spray. The primary objectives are to make the drug candidate ready for late-stage clinical development and Pharma Holdings rigged for commercial partnering discussions. This will be achieved by; - gaining clinical evidence on the LTX-109 nasal spray antiviral efficacy by executing a phase IIa clinical trial, making the drug ready for phase IIb/III clinical trails during Q4 2026 - gaining scientific advice from relevant medicines agencies on the most appropriate way to generate robust evidence on the LTX-109 nasal spray clinical development towards market authorization - developing the nasal spray clinical pathway beyond the phase IIa trial -developing and testing of scale-up activities of the LTX-109 and nasal spray production - development of a commercial strategy